The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Antifungal Drugs
Open accessAbstract
We reviewed the licensed antifungal drugs and summarized their mechanisms of action, pharmacological profiles, and susceptibility to specific fungi. Approved antimycotics inhibit 1,3-β-d-glucan synthase, lanosterol 14-α-demethylase, protein, and deoxyribonucleic acid biosynthesis, or sequestrate ergosterol. Their most severe side effects are hepatotoxicity, nephrotoxicity, and myelotoxicity. Whereas triazoles exhibit the most significant drug–drug interactions, echinocandins exhibit almost none. The antifungal resistance may be developed across most pathogens and includes drug target overexpression, efflux pump activation, and amino acid substitution. The experimental antifungal drugs in clinical trials are also reviewed. Siderophores in the Trojan horse approach or the application of siderophore biosynthesis enzyme inhibitors represent the most promising emerging antifungal therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Bongomin, F., Gago, S., Oladele, R., & Denning, D. (2017) · Journal of Fungi · doi:10.3390/jof3040057 · Cited by 2,953 · cited 1×
“The recent annual incidence of invasive aspergillosis, candidiasis, and mucormycosis is over 300,000, 750,000, and 10,000 cases, respectively [3].”
BackgroundUllmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.002 · Cited by 1,556
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353
Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12039 · Cited by 1,217 · cited 13×
“AMB is highly fungicidal against Candida genera [9] and Aspergillus fumigatus and A. flavus [10].”
BackgroundInfluentialFusarium Infections in Immunocompromised Patients
Nucci, M., & Anaissie, E. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00014-07 · Cited by 983
Global Epidemiology of Mucormycosis
Prakash, H., & Chakrabarti, A. (2019) · Journal of Fungi · doi:10.3390/jof5010026 · Cited by 938
The antifungal pipeline: a reality check
Perfect, J. R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.46 · Cited by 866
Amphotericin B formulations: a comparative review of efficacy and toxicity
Hamill, R. J. (2013) · Drugs · doi:10.1007/s40265-013-0069-4 · Cited by 807 · cited 1×
“Three lipidic formulations are commercially available: AMB lipid complex (ABLC), liposomal AMB (LAMB), and AMB colloidal dispersion (ABCD) [29].”
MethodVermes, A. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.2.171 · Cited by 803
Mechanisms of Antifungal Drug Resistance
Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., & Perlin, D. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019752 · Cited by 647
Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer
Parker, W. B. (2009) · Chemical Reviews · doi:10.1021/cr900028p · Cited by 622 · cited 1×
“This compound inhibits the primary source of thymidine in DNA biosynthesis, thymidylate synthetase, due to the enzyme’s inability to remove the fluorine atom [25].”
BackgroundVerweij, P. E., Chowdhary, A., Melchers, W. J. G., & Meis, J. F. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ885 · Cited by 561
Tortorano, A. M., Richardson, M., Roilides, E., van Diepeningen, A., Caira, M., Munoz, P., Johnson, E., Meletiadis, J., Pana, Z.-D., Lackner, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12465 · Cited by 523
Antifungal drug resistance: evolution, mechanisms and impact
Revie, N. M., Iyer, K. R., Robbins, N., & Cowen, L. E. (2018) · Current Opinion in Microbiology · doi:10.1016/j.mib.2018.02.005 · Cited by 516
Pharmacokinetic/Pharmacodynamic Profile of Posaconazole
Li, Y., Theuretzbacher, U., Clancy, C. J., Nguyen, M. H., & Derendorf, H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11319340-000000000-00000 · Cited by 450
Fusarium: Molecular Diversity and Intrinsic Drug Resistance
Al-Hatmi, A. M. S., Meis, J. F., & de Hoog, G. S. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005464 · Cited by 432
Emerging Threats in Antifungal-Resistant Fungal Pathogens
Sanglard, D. (2016) · Frontiers in Medicine · doi:10.3389/fmed.2016.00011 · Cited by 416
The Clinical Pharmacokinetics of Itraconazole: An Overview
Heykants, J., Van Peer, A., Van de Velde, V., Van Rooy, P., Meuldermans, W., Lavrijsen, K., Woestenborghs, R., Van Cutsem, J., & Cauwenbergh, G. (1989) · Mycoses · doi:10.1111/j.1439-0507.1989.tb02296.x · Cited by 404
Antifungal drug resistance among Candida species: mechanisms and clinical impact
Sanguinetti, M., Posteraro, B., & Lass‐Flörl, C. (2015) · Mycoses · doi:10.1111/myc.12330 · Cited by 394
Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
Bellmann, R., & Smuszkiewicz, P. (2017) · Infection · doi:10.1007/s15010-017-1042-z · Cited by 389
Echinocandin resistance in Candida.
Perlin, D. S. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ791 · Cited by 374
Nett, J. E., & Andes, D. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.012 · Cited by 351
It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug
Mesa-Arango, A. C., Scorzoni, L., & Zaragoza, O. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00286 · Cited by 311 · cited 2×
“Second, AMB induces the accumulation of reactive oxygen species (ROS), resulting in DNA, protein, mitochondrial, and membrane damage [23].”
BackgroundScedosporium apiospermum: changing clinical spectrum of a therapy-refractory opportunist*
Guarro, J., Kantarcioglu, A. S., Horré, R., Luis Rodriguez-Tudela, J., Cuenca Estrella, M., Berenguer, J., & Sybren De Hoog, G. (2006) · Medical Mycology · doi:10.1080/13693780600752507 · Cited by 297
Azole Resistance in Aspergillus fumigatus: A Consequence of Antifungal Use in Agriculture?
Berger, S., El Chazli, Y., Babu, A. F., & Coste, A. T. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.01024 · Cited by 256
Clinical Pharmacokinetics of Fluconazole
Debruyne, D., & Ryckelynck, J.-P. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199324010-00002 · Cited by 255
Polyene Macrolide Antibiotics and their Applications in Human Therapy
Zotchev, S. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033368448 · Cited by 251
Aspiring Antifungals: Review of Current Antifungal Pipeline Developments
Gintjee, T., Donnelley, M., & Thompson, G. (2020) · Journal of Fungi · doi:10.3390/jof6010028 · Cited by 225
Antifungal drugs: What brings the future?
Van Daele, R., Spriet, I., Wauters, J., Maertens, J., Mercier, T., Van Hecke, S., & Brüggemann, R. (2019) · Medical Mycology · doi:10.1093/mmy/myz012 · Cited by 223
Bhattacharya, S., Esquivel, B. D., & White, T. C. (2018) · mBio · doi:10.1128/mbio.01291-18 · Cited by 210 · cited 1×
“Ergosterol biosynthesis is regulated by 25 known ERG enzymes [66]; their alterations (ERG3, ERG5, ERG11), gene deletion (ERG11), and harbored mutations (ERG1, ERG2, ERG6, ERG11) lead to the decreased AMB sensitivity in Candida species [67].”
BackgroundSagatova, A. A., Keniya, M. V., Wilson, R. K., Monk, B. C., & Tyndall, J. D. A. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00925-15 · Cited by 210
Hope on the Horizon: Novel Fungal Treatments in Development
Rauseo, A. M., Coler-Reilly, A., Larson, L., & Spec, A. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa016 · Cited by 199
New Horizons in Antifungal Therapy
Pianalto, K., & Alspaugh, J. (2016) · Journal of Fungi · doi:10.3390/jof2040026 · Cited by 190
SUSCEPTIBILITY TEST FOR FUNGI: CLINICAL AND LABORATORIAL CORRELATIONS IN MEDICAL MYCOLOGY
ALASTRUEY-IZQUIERDO, A., MELHEM, M. S. C., BONFIETTI, L. X., & RODRIGUEZ-TUDELA, J. L. (2015) · Revista do Instituto de Medicina Tropical de São Paulo · doi:10.1590/s0036-46652015000700011 · Cited by 184
ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children
Warris, A., Lehrnbecher, T., Roilides, E., Castagnola, E., Brüggemann, R. J. M., & Groll, A. H. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.05.019 · Cited by 183
The Iron Tug-of-War between Bacterial Siderophores and Innate Immunity
Golonka, R., Yeoh, B. S., & Vijay-Kumar, M. (2019) · Journal of Innate Immunity · doi:10.1159/000494627 · Cited by 172
Antifungal drugs: New insights in research & development
Nicola, A. M., Albuquerque, P., Paes, H. C., Fernandes, L., Costa, F. F., Kioshima, É. S., Abadio, A. K. R., Bocca, A. L., & Felipe, M. S. S. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.10.008 · Cited by 171
Bliss, J. M., Basavegowda, K. P., Watson, W. J., Sheikh, A. U., & Ryan, R. M. (2008) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31815bb69d · Cited by 159
Kofla, G., & Ruhnke, M. (2011) · European Journal of Medical Research · doi:10.1186/2047-783x-16-4-159 · Cited by 153
Antifungal drugs during pregnancy: an updated review
Pilmis, B., Jullien, V., Sobel, J. D., Lecuit, M., Lortholary, O., & Charlier, C. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku355 · Cited by 153
The antifungal arsenal: alternative drugs and future targets
Wiederhold, N. P. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.09.002 · Cited by 149 · cited 3×
“In ergosterol biosynthesis, modified tetrazoles (VT-1129, 1161, 1598; Figure 7A–C) show higher specificity to the fungal Cyp51 [84].”
BackgroundInfluentialBeardsley, J., Halliday, C. L., Chen, S. C. ‐., & Sorrell, T. C. (2018) · Future Microbiology · doi:10.2217/fmb-2018-0059 · Cited by 146
Echinocandins in antifungal pharmacotherapy
Patil, A., & Majumdar, S. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12780 · Cited by 145
Siderophores for molecular imaging applications
Petřík, M., Zhai, C., Haas, H., & Decristoforo, C. (2016) · Clinical and Translational Imaging · doi:10.1007/s40336-016-0211-x · Cited by 142
Molecular basis of antifungal drug resistance in yeasts
Morio, F., Jensen, R. H., Le Pape, P., & Arendrup, M. C. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.05.012 · Cited by 114 · cited 2×
“glabrata [58], and Aspergillus species [59], the acquired resistance has been a consequence of long-term therapies, widespread prophylaxis, or use of antifungals in agriculture, especially in the case of triazoles [60].”
BackgroundBreaking a pathogen's iron will: Inhibiting siderophore production as an antimicrobial strategy
Lamb, A. L. (2015) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2015.05.001 · Cited by 111
Johnson, M. E., Katiyar, S. K., & Edlind, T. D. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01811-10 · Cited by 107
Kahlmeter, G., Giske, C. G., Kirn, T. J., & Sharp, S. E. (2019) · Journal of Clinical Microbiology · doi:10.1128/jcm.01129-19 · Cited by 105
Rybak, J. M., Marx, K. R., Nishimoto, A. T., & Rogers, P. D. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1652 · Cited by 103
Azole-induced cell wall carbohydrate patches kill Aspergillus fumigatus
Geißel, B., Loiko, V., Klugherz, I., Zhu, Z., Wagener, N., Kurzai, O., van den Hondel, C. A. M. J. J., & Wagener, J. (2018) · Nature Communications · doi:10.1038/s41467-018-05497-7 · Cited by 103
Overview of Treatment Approaches for Fungal Infections
Carmona, E. M., & LIMPER, A. H. (2017) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2017.04.003 · Cited by 101
Meletiadis, J., Antachopoulos, C., Stergiopoulou, T., Pournaras, S., Roilides, E., & Walsh, T. J. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00345-07 · Cited by 100
Alkhazraji, S., Gebremariam, T., Alqarihi, A., Gu, Y., Mamouei, Z., Singh, S., Wiederhold, N. P., Shaw, K. J., & Ibrahim, A. S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01735-19 · Cited by 97 · cited 1×
“The inositol acyltransferase inhibitor Fosmanogepix (APX001, Figure 7G) prevents microorganism colonization/adhesion [86] and is effective against pulmonary scedosporiosis or fusariosis in immunocompromised mice [88].”
BackgroundLeblanc, C., Prudhomme, T., Tabouret, G., Ray, A. A., Burbaud, S., Cabantous, S., Mourey, L., Guilhot, C., & Chalut, C. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1003097 · Cited by 95
Hull, C. M., Bader, O., Parker, J. E., Weig, M., Gross, U., Warrilow, A. G. S., Kelly, D. E., & Kelly, S. L. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01145-12 · Cited by 90
Caramalho, R., Tyndall, J. D. A., Monk, B. C., Larentis, T., Lass‐Flörl, C., & Lackner, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-16123-9 · Cited by 89
Structure-Antifungal Activity Relationships of Polyene Antibiotics of the Amphotericin B Group
Tevyashova, A. N., Olsufyeva, E. N., Solovieva, S. E., Printsevskaya, S. S., Reznikova, M. I., Trenin, A. S., Галатенко, О. А., Treshalin, I. D., Переверзева, Э. Р., Павловна, М. Е., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00270-13 · Cited by 88
Mesa-Arango, A. C., Rueda, C., Román, E., Quintin, J., Terrón, M. C., Luque, D., Netea, M. G., Pla, J., & Zaragoza, O. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02681-15 · Cited by 86
1,3-beta-Glucan Synthase: A Useful Target for Antifungal Drugs
Liu, J., & Balasubramanian, M. K. (2001) · Current Drug Targets - Infectious Disorders · doi:10.2174/1568005014606107 · Cited by 85
Aspergillus terreus: Novel lessons learned on amphotericin B resistance
Posch, W., Blatzer, M., Wilflingseder, D., & Lass‐Flörl, C. (2018) · Medical Mycology · doi:10.1093/mmy/myx119 · Cited by 82
Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia
Momparler, R. L. (2013) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-2-20 · Cited by 77
Schell, W. A., Jones, A. M., Garvey, E. P., Hoekstra, W. J., Schotzinger, R. J., & Alexander, B. D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01817-16 · Cited by 74 · cited 3×
“Future antifungal therapy may benefit from these substances including tetrazoles VT-1129 (A), VT-1161 (B), VT-1598 (C); triazole PC1244 (D); echinocandin rezafungin (E); triterpenoid Ibrexafungerp (F); inositol transferase inhibitor Fosmanogepix (G); dihydroorotate dehydrogenase inhibitor Olorofim (H); histone deacety…”
Acylhydrazones as Antifungal Agents Targeting the Synthesis of Fungal Sphingolipids
Lazzarini, C., Haranahalli, K., Rieger, R. A., Ananthula, H. K., Desai, P. B., Ashbaugh, A., Linke, M. J., Cushion, M. T., Ruzsicska, B. P., Haley, J. D., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00156-18 · Cited by 73
Potential targets for the development of new antifungal drugs
Su, H., Han, L., & Huang, X. (2018) · The Journal of Antibiotics · doi:10.1038/s41429-018-0100-9 · Cited by 69
Voriconazole in the management of nosocomial invasive fungal infections
Pemán, J., Salavert, M., Cant�n, E., Jarque, I., Rom, E., Zaragoza, R., Viudes, �., & Gobernado, M. (2006) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.2006.2.2.129 · Cited by 68
Advances in the antimicrobial and therapeutic potential of siderophores
Ribeiro, M., & Simões, M. V. (2019) · Environmental Chemistry Letters · doi:10.1007/s10311-019-00887-9 · Cited by 65
Modulating host immune responses to fight invasive fungal infections
Scriven, J. E., Tenforde, M. W., Levitz, S. M., & Jarvis, J. N. (2017) · Current Opinion in Microbiology · doi:10.1016/j.mib.2017.10.018 · Cited by 59
Mycoviruses mediate mycotoxin regulation in Aspergillus ochraceus
Nerva, L., Chitarra, W., Siciliano, I., Gaiotti, F., Ciuffo, M., Forgia, M., Varese, G. C., & Turina, M. (2018) · Environmental Microbiology · doi:10.1111/1462-2920.14436 · Cited by 57
Susceptibility testing of fungi to antifungal drugs
Sanguinetti, M., & Posteraro, B. (2018) · Journal of Fungi · doi:10.3390/jof4030110 · Cited by 55
Combination Therapy for Invasive Fungal Infections
Livengood, S. J., Drew, R. H., & Perfect, J. R. (2020) · Current Fungal Infection Reports · doi:10.1007/s12281-020-00369-4 · Cited by 54
Lestner, J. M., Smith, P. B., Cohen‐Wolkowiez, M., Benjamin, D. K., & Hope, W. W. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12025 · Cited by 50
Kumar, A., Zarychanski, R., Pisipati, A., Kumar, A., Kethireddy, S., & Bow, E. J. (2018) · Mycology: An International Journal on Fungal Biology · doi:10.1080/21501203.2017.1421592 · Cited by 47
Costa, C., Ponte, A., Pais, P., Santos, R., Cavalheiro, M., Yaguchi, T., Chibana, H., & Teixeira, M. C. (2015) · PLOS ONE · doi:10.1371/journal.pone.0135110 · Cited by 46 · cited 1×
“glabrata to 5-FC increased after deletion of the CgFPS1 and CgFPS2 homologue encoding plasma membrane aquaglyceroporins that are required for osmotic stress resistance [70].”
BackgroundMechanistic Basis of pH-Dependent 5-Flucytosine Resistance in Aspergillus fumigatus
Gsaller, F., Furukawa, T., Carr, P. D., Rash, B. M., Jöchl, C., Bertuzzi, M., Bignell, E., & Bromley, M. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02593-17 · Cited by 46
Dosing of antifungal agents in obese people
Payne, K. D., & Hall, R. G. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2016.1128822 · Cited by 39
Susceptibility ofCandida glabratabiofilms to echinocandins: alterations in the matrix composition
Rodrigues, C. F., Rodrigues, M. E., & Henriques, M. (2018) · Biofouling · doi:10.1080/08927014.2018.1472244 · Cited by 39
Haranahalli, K., Lazzarini, C., Sun, Y., Zambito, J., Pathiranage, S., McCarthy, J., Mallamo, J. P., Poeta, M. D., & Ojima, I. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01004 · Cited by 39
Yao, J., Liu, H., Zhou, T., Chen, H., Miao, Z., Sheng, C., & Zhang, W. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.01.054 · Cited by 35
Ahmad, S., Bhattacharya, D., Kar, S. K., Ranganathan, A., Kaer, L. V., & Das, G. (2019) · Infection and Immunity · doi:10.1128/iai.00291-19 · Cited by 35
Phosphopantetheinyl transferase inhibition and secondary metabolism
Foley, T. L., Young, B. S., & Burkart, M. D. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07425.x · Cited by 33
Mycovirus therapy for invasive pulmonary aspergillosis?
van de Sande, W. W. J., & Vonk, A. G. (2018) · Medical Mycology · doi:10.1093/mmy/myy073 · Cited by 33
del Campo, J. S. M., Vogelaar, N. J., Tolani, K., Kizjakina, K., Harich, K. C., & Sobrado, P. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00666 · Cited by 32
Antifungal Drugs for Invasive Candida Infections (ICI) in Neonates: Future Perspectives
Bersani, I., Piersigilli, F., Goffredo, B. M., Santisi, A., Cairoli, S., Ronchetti, M. P., & Auriti, C. (2019) · Frontiers in Pediatrics · doi:10.3389/fped.2019.00375 · Cited by 31
Non-invasive and invasive diagnoses of aspergillosis in a rat model by mass spectrometry
Luptáková, D., Pluháček, T., Petřík, M., Novák, J., Palyzová, A., Sokolová, L., Škríba, A., Šedivá, B., Lemr, K., & Havlíček, V. (2017) · Scientific Reports · doi:10.1038/s41598-017-16648-z · Cited by 30
Self-citationCutler, J. E., Corti, M., Lambert, P., Ferris, M. J., & Xin, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022030 · Cited by 29
Al‐Hatmi, A. M. S., Normand, A., Ranque, S., Piarroux, R., de Hoog, S., Meletiadis, J., & Meis, J. F. G. M. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01671-16 · Cited by 27
Mammen, M. P., Armas, D. R., Hughes, F. H., Hopkins, A. M., Fisher, C. L., Resch, P. A., Rusalov, D., Sullivan, S. M., & Smith, L. R. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00969-19 · Cited by 25
Ping, B., Zhu, Y., Gao, Y., Yue, C., & Wu, B. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1693-5 · Cited by 24
Colley, T., Sharma, C., Alanio, A., Kimura, G., Daly, L., Nakaoki, T., Nishimoto, Y., Bretagne, S., Kizawa, Y., Strong, P., et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz302 · Cited by 17
Cited by
Fungal infections in humans: the silent crisis
Kainz, K., Bauer, M. A., Madeo, F., & Carmona-Gutierrez, D. (2020) · Microbial Cell · doi:10.15698/mic2020.06.718 · Cited by 369
Kaempferol: Antimicrobial Properties, Sources, Clinical, and Traditional Applications
Periferakis, A., Periferakis, K., Badarau, I. A., Petran, E. M., Popa, D. C., Caruntu, A., Costache, R. S., Scheau, C., Caruntu, C., & Costache, D. O. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315054 · Cited by 362
Diagnosis of invasive fungal infections: challenges and recent developments
Fang, W., Wu, J., Cheng, M., Zhu, X., Du, M., Chen, C., Liao, W., Zhi, K., & Pan, W. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00926-2 · Cited by 356
Cyclic peptide drugs approved in the last two decades (2001–2021)
Zhang, H., & Chen, S. (2022) · RSC Chemical Biology · doi:10.1039/d1cb00154j · Cited by 319
Echinocandins – structure, mechanism of action and use in antifungal therapy
Szymański, M., Chmielewska, S., Czyżewska, U., Malinowska, M., & Tylicki, A. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2050224 · Cited by 270
Metadata
- Authors
- Houšť, J., Spížek, J., & Havlíček, V.
- Venue
- Metabolites
- Publisher
- MDPI AG
- Published
- 2020-03-12
- Volume
- 10
- Issue
- 3
- Pages
- 106
- ISSN
- 2218-1989 (ISSN-L)
- OpenAlex
- W4230956988
- Cited by
- 254
- References
- 90
- FWCI
- 3.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.